Somewhat Positive Media Coverage Somewhat Unlikely to Impact Immune Design Corp. (IMDZ) Stock Price
News articles about Immune Design Corp. (NASDAQ:IMDZ) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Immune Design Corp. earned a news sentiment score of 0.18 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 46.580700538865 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the media stories that may have effected Accern Sentiment’s scoring:
- Search Over 500 Medications – Viagra Go Generic (naturalgasnow.org)
- ASAP – Kamagra Oral Jelly Walgreens (careersherpa.net)
- 24h Customer Support – Buy Cialis Online Now (taher.com)
- Workers’ health plans aren’t immune to Obamacare volatility, insurance chief says (houstonchronicle.com)
Shares of Immune Design Corp. (NASDAQ IMDZ) opened at 8.15 on Friday. The company’s 50-day moving average price is $9.61 and its 200-day moving average price is $7.45. Immune Design Corp. has a 52-week low of $4.50 and a 52-week high of $13.05. The stock’s market cap is $208.79 million.
Immune Design Corp. (NASDAQ:IMDZ) last issued its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.54) EPS for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.11. The company had revenue of $0.73 million for the quarter, compared to analyst estimates of $1.50 million. Immune Design Corp. had a negative return on equity of 59.14% and a negative net margin of 324.33%. Analysts expect that Immune Design Corp. will post ($2.39) earnings per share for the current year.
A number of research analysts have recently weighed in on IMDZ shares. Zacks Investment Research upgraded Immune Design Corp. from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a research report on Tuesday, July 18th. ValuEngine upgraded Immune Design Corp. from a “sell” rating to a “hold” rating in a research report on Friday, August 11th. Cowen and Company restated a “buy” rating on shares of Immune Design Corp. in a research report on Tuesday, June 6th. Jefferies Group LLC restated a “buy” rating and issued a $18.00 price target (up previously from $16.00) on shares of Immune Design Corp. in a research report on Friday, May 19th. Finally, BidaskClub cut Immune Design Corp. from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 5th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $14.50.
COPYRIGHT VIOLATION WARNING: This news story was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at https://www.thecerbatgem.com/2017/08/26/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-immune-design-corp-imdz-stock-price.html.
In other news, Director Lewis W. Coleman purchased 12,000 shares of the business’s stock in a transaction dated Tuesday, July 11th. The shares were bought at an average cost of $9.05 per share, for a total transaction of $108,600.00. Following the completion of the acquisition, the director now directly owns 40,000 shares in the company, valued at approximately $362,000. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Wayne Gombotz sold 10,000 shares of the business’s stock in a transaction dated Tuesday, August 1st. The shares were sold at an average price of $11.43, for a total value of $114,300.00. Following the completion of the sale, the insider now owns 33,054 shares in the company, valued at $377,807.22. The disclosure for this sale can be found here. Over the last 90 days, insiders bought 30,000 shares of company stock worth $272,760. Corporate insiders own 42.90% of the company’s stock.
About Immune Design Corp.
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.
Receive News & Stock Ratings for Immune Design Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design Corp. and related stocks with our FREE daily email newsletter.